Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exenatide is the first-in-class incretin mimetic for the treatment of type 2 diabetes. OBJECTIVE: To assess exenatide's mechanism of action, therapeutic and adverse effects. METHODS: Pharmacokinetics and pharmacodynamics of exenatide were reviewed, as well Phase I, II and III clinical trials, and postmarket reports. RESULTS/CONCLUSION: Exenatide improves fasting plasma glucose and HbA1c in type 2 diabetic patients not controlled on other antidiabetic drugs, due to its effects on glucose-dependent stimulation on insulin secretion, suppression elevated glucagon secretion, slowing the accelerated rate of gastric emptying, reduction of food intake and possible beta-cell preservation. Nausea and vomiting were the most common and dose-related side effects. Rare reports of acute pancreatitis do not appear greater than the rate in the general population of patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 8×
“The authors believe that the greater weight loss compared with the pivotal Phase III trials [23-25] is related to the encouragement and nutritional and activity support given to their patients.”
BackgroundInfluentialMcGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“compared the insulin secretion after oral glucose administration between type 2 diabetic patients and matched healthy controls and showed that the enhanced insulin secretion after oral glucose was attenuated in patients with T2DM [11] .”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 9×
“The authors believe that the greater weight loss compared with the pivotal Phase III trials [23-25] is related to the encouragement and nutritional and activity support given to their patients.”
BackgroundMethodInfluentialPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Studies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837 · cited 1×
“It had been demonstrated that glucagon secretion in T2DM is not suppressed after a carbohydrate-rich meal [7,8] .”
BackgroundHeine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626 · cited 1×
“It had been demonstrated that glucagon secretion in T2DM is not suppressed after a carbohydrate-rich meal [7,8] .”
Background
Cited by
Ballestri, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1724 · Cited by 262
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
“Exenatide* and liraglutide, the two earliest GLP-1 RAs, were approved by the US Food and Drug Administration in 2005 and 2010, respectively.(6,7) Albiglutide and lixisenatide were approved by the European Medicines Agency in 2013.”
BackgroundSun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
Wu, H., Sui, C., Xia, F., Zhai, H., Zhang, H., Xu, H., Weng, P., & Lu, Y. (2016) · Endocrine Research · doi:10.3109/07435800.2015.1015726 · Cited by 15
“The GLP-1 receptor has been identified in skeletal muscle tissue (19).”
BackgroundInfluentialEffect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome
González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., & Ramos-Zavala, M. G. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0025 · Cited by 14
Metadata
- Authors
- Wajcberg, E., & Tavaria, A.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2008-12-16
- Volume
- 10
- Issue
- 1
- Pages
- 135-142
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1996602059
- Cited by
- 41
- References
- 12
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1517/14656560802611832
- The paper
- Wajcberg, E., & Tavaria, A. (2009). Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560802611832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.